scholarly journals Speech- and Language-Based Classification of Alzheimer’s Disease: A Systematic Review

2022 ◽  
Vol 9 (1) ◽  
pp. 27
Author(s):  
Inês Vigo ◽  
Luis Coelho ◽  
Sara Reis
Keyword(s):  
Systematic Review ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Best Practices ◽  
Early Stage ◽  
Low Cost ◽  
Clinical Stage ◽  
Invasive Procedure ◽  
The Impact

Background: Alzheimer’s disease (AD) has paramount importance due to its rising prevalence, the impact on the patient and society, and the related healthcare costs. However, current diagnostic techniques are not designed for frequent mass screening, delaying therapeutic intervention and worsening prognoses. To be able to detect AD at an early stage, ideally at a pre-clinical stage, speech analysis emerges as a simple low-cost non-invasive procedure. Objectives: In this work it is our objective to do a systematic review about speech-based detection and classification of Alzheimer’s Disease with the purpose of identifying the most effective algorithms and best practices. Methods: A systematic literature search was performed from Jan 2015 up to May 2020 using ScienceDirect, PubMed and DBLP. Articles were screened by title, abstract and full text as needed. A manual complementary search among the references of the included papers was also performed. Inclusion criteria and search strategies were defined a priori. Results: We were able: to identify the main resources that can support the development of decision support systems for AD, to list speech features that are correlated with the linguistic and acoustic footprint of the disease, to recognize the data models that can provide robust results and to observe the performance indicators that were reported. Discussion: A computational system with the adequate elements combination, based on the identified best-practices, can point to a whole new diagnostic approach, leading to better insights about AD symptoms and its disease patterns, creating conditions to promote a longer life span as well as an improvement in patient quality of life. The clinically relevant results that were identified can be used to establish a reference system and help to define research guidelines for future developments.

Fluoxetine Protects against Dendritic Spine Loss in Middle-aged APPswe/PSEN1dE9 Double Transgenic Alzheimer’s Disease Mice

2020 ◽  
Vol 17 (1) ◽  
pp. 93-103 ◽  
Author(s):  
Jing Ma ◽  
Yuan Gao ◽  
Wei Tang ◽  
Wei Huang ◽  
Yong Tang
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Dendritic Spines ◽  
Dendritic Spine ◽  
Early Stage ◽  
Learning Ability ◽  
Middle Aged ◽  
Protein Levels ◽  
Spine Pathology ◽  
The Impact

Background: Studies have suggested that cognitive impairment in Alzheimer’s disease (AD) is associated with dendritic spine loss, especially in the hippocampus. Fluoxetine (FLX) has been shown to improve cognition in the early stage of AD and to be associated with diminishing synapse degeneration in the hippocampus. However, little is known about whether FLX affects the pathogenesis of AD in the middle-tolate stage and whether its effects are correlated with the amelioration of hippocampal dendritic dysfunction. Previously, it has been observed that FLX improves the spatial learning ability of middleaged APP/PS1 mice. Objective: In the present study, we further characterized the impact of FLX on dendritic spines in the hippocampus of middle-aged APP/PS1 mice. Results: It has been found that the numbers of dendritic spines in dentate gyrus (DG), CA1 and CA2/3 of hippocampus were significantly increased by FLX. Meanwhile, FLX effectively attenuated hyperphosphorylation of tau at Ser396 and elevated protein levels of postsynaptic density 95 (PSD-95) and synapsin-1 (SYN-1) in the hippocampus. Conclusion: These results indicated that the enhanced learning ability observed in FLX-treated middle-aged APP/PS1 mice might be associated with remarkable mitigation of hippocampal dendritic spine pathology by FLX and suggested that FLX might be explored as a new strategy for therapy of AD in the middle-to-late stage.

scholarly journals Plasma contact factors as novel biomarkers for diagnosing Alzheimer’s disease

2021 ◽  
Vol 9 (1) ◽  
Author(s):  
Jung Eun Park ◽  
Do Sung Lim ◽  
Yeong Hee Cho ◽  
Kyu Yeong Choi ◽  
Jang Jae Lee ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Early Stage ◽  
Clinical Stage ◽  
Area Under The Curve ◽  
Contact System ◽  
Plasma Diagnostic ◽  
Vascular Abnormalities ◽  
Prodromal Ad ◽  
Novel Biomarkers

Abstract Background Alzheimer’s disease (AD) is the most common cause of dementia and most of AD patients suffer from vascular abnormalities and neuroinflammation. There is an urgent need to develop novel blood biomarkers capable of diagnosing Alzheimer’s disease (AD) at very early stage. This study was performed to find out new accurate plasma diagnostic biomarkers for AD by investigating a direct relationship between plasma contact system and AD. Methods A total 101 of human CSF and plasma samples from normal and AD patients were analyzed. The contact factor activities in plasma were measured with the corresponding specific peptide substrates. Results The activities of contact factors (FXIIa, FXIa, plasma kallikrein) and FXa clearly increased and statistically correlated as AD progresses. We present here, for the first time, the FXIIa cut-off scores to as: > 26.3 U/ml for prodromal AD [area under the curve (AUC) = 0.783, p < 0.001] and > 27.2 U/ml for AD dementia (AUC = 0.906, p < 0.001). We also describe the cut-off scores from the ratios of CSF Aβ1–42 versus the contact factors. Of these, the representative ratio cut-off scores of Aβ1–42/FXIIa were to be: < 33.8 for prodromal AD (AUC = 0.965, p < 0.001) and < 27.44 for AD dementia (AUC = 1.0, p < 0.001). Conclusion The activation of plasma contact system is closely associated with clinical stage of AD, and FXIIa activity as well as the cut-off scores of CSF Aβ1–42/FXIIa can be used as novel accurate diagnostic AD biomarkers.

scholarly journals A Deep Siamese Convolution Neural Network for Multi-Class Classification of Alzheimer Disease

2020 ◽  
Vol 10 (2) ◽  
pp. 84 ◽  
Author(s):  
Atif Mehmood ◽  
Muazzam Maqsood ◽  
Muzaffar Bashir ◽  
Yang Shuyuan
Keyword(s):  
Neural Network ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Convolutional Neural Network ◽  
State Of The Art ◽  
Early Stage ◽  
The State ◽  
Test Accuracy ◽  
Learning Approaches

Alzheimer’s disease (AD) may cause damage to the memory cells permanently, which results in the form of dementia. The diagnosis of Alzheimer’s disease at an early stage is a problematic task for researchers. For this, machine learning and deep convolutional neural network (CNN) based approaches are readily available to solve various problems related to brain image data analysis. In clinical research, magnetic resonance imaging (MRI) is used to diagnose AD. For accurate classification of dementia stages, we need highly discriminative features obtained from MRI images. Recently advanced deep CNN-based models successfully proved their accuracy. However, due to a smaller number of image samples available in the datasets, there exist problems of over-fitting hindering the performance of deep learning approaches. In this research, we developed a Siamese convolutional neural network (SCNN) model inspired by VGG-16 (also called Oxford Net) to classify dementia stages. In our approach, we extend the insufficient and imbalanced data by using augmentation approaches. Experiments are performed on a publicly available dataset open access series of imaging studies (OASIS), by using the proposed approach, an excellent test accuracy of 99.05% is achieved for the classification of dementia stages. We compared our model with the state-of-the-art models and discovered that the proposed model outperformed the state-of-the-art models in terms of performance, efficiency, and accuracy.

scholarly journals Attracting New Investigators to Alzheimer’s Disease Research: Outcomes of Increased Funding and Outreach

2020 ◽  
Author(s):  
Pragati Katiyar ◽  
Catherine Nagy ◽  
Samir Sauma ◽  
Marie A Bernard
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Brain Aging ◽  
Early Stage ◽  
Research Field ◽  
National Institutes Of Health ◽  
Fiscal Year ◽  
Disease Research ◽  
Nih Funding ◽  
The Impact

Abstract Since 2015, the National Institute on Aging (NIA), National Institutes of Health (NIH), has experienced significant increases in funding for Alzheimer’s disease and Alzheimer’s disease-related dementias (AD/ADRD). This analysis assesses the impact of these funds on expanding the AD/ADRD workforce. NIA administered 860 awards to 695 AD/ADRD R01 awardees during fiscal year 2015–2018. Twenty-nine percent of awardees were new or early-stage investigators, while 38% were new to the AD/ADRD research field (NTF). Among these NTFs, 59% were established investigators, that is, experts with NIH funding in another discipline but new to AD/ADRD research. Awards were further analyzed to determine the focus of their research based on International Alzheimer’s Disease Research Portfolio (IADRP) categories. Forty-six percent were focused on Molecular Pathogenesis and Physiology. Other IADRP categories, including Diagnosis, Assessment, and Disease Monitoring and Translational Research and Clinical Interventions, represented 5%–15% of awards. Significantly, NTF investigators received 50%, 42%, and 70% of the total grants awarded in Population Studies, Dementia Care, and Brain Aging, respectively, suggesting that NTF investigators are filling research gaps. While these results suggest that enhanced funding is associated with recruitment of new talent, opportunities for further growth remain, particularly related to care, caregiving, and health disparities.

Possible selves and illness: A comparison of individuals with Parkinson's disease, early-stage Alzheimer's disease, and healthy older adults

2003 ◽  
Vol 27 (1) ◽  
pp. 1-11 ◽  
Author(s):  
Leslie D. Frazier ◽  
Victoria Cotrell ◽  
Karen Hooker
Keyword(s):  
Alzheimer’S Disease ◽  
Older Adults ◽  
Parkinson’S Disease ◽  
Alzheimer's Disease ◽  
Parkinson's Disease ◽  
Possible Selves ◽  
Early Stage ◽  
Healthy Older Adults ◽  
Patient Groups ◽  
The Impact

This study examined how future self-representations are affected by two different chronic illnesses, one focused on cognitive losses, early-stage Alzheimer's disease (AD), and one focused on physical losses, Parkinson's disease (PD). The impact of illness on possible selves (perceptions of self in the future) was made salient by a comparison with healthy older adults in order to better understand developmental issues in later life. Findings show that although there were no differences in the total number of domains reported by the groups, specific domains were reported differently by patient groups and all domains were likely to become infused with illness. As expected, patient groups had less self-efficacy and lower outcome expectancies for their future selves, and PD patients reported less distance from their feared selves. Although these findings are intuitive, this is the first empirical effort to document the impact of illness on older adults' self-representations. Group differences are explained in terms of disease context, and the importance of possible selves and self-regulatory functions as therapeutic mechanisms for adaptation to illness are emphasised.

Performance of healthy elderly with Alzheimer's disease at an early stage in executive function and language

2011 ◽  
Vol 26 (S2) ◽  
pp. 498-498
Author(s):  
M.T. Santos ◽  
G.C. Couto ◽  
J.C. Achieri ◽  
C.A. Júnior
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Early Stage ◽  
The Elderly ◽  
Screening Tests ◽  
Healthy Elderly ◽  
Initial Stage ◽  
Significant Difference ◽  
Common Causes ◽  
The Impact

Dementia are increasingly prevalent in population. The most common causes of dementia is Alzheimer's disease (AD). Screening tests have been used for the premature diagnosis of Alzheimer Disease (AD), specifically in the executive functions and language, which are compromised at an initial stage. However, the necessity standardized means and validated for our middle, to show oneself a pressing subject.ObjectiveTo analyze the impact of the length of sentences in the abstraction of proverbs in the Screening Test for Alzheimer's disease with Proverbs (TRDAP), healthy elderly and with Alzheimer's disease at early stage.MethodSurvey document in the database, analyzing the responses of the elderly (abstract or concrete interpretation of proverbs), relating the length of sentences (sayings) of stage B of TRDAP with the diagnosis of Alzheimer's disease and the interference of age and schooling.ResultsHealthy older people showed greater capacity for abstraction than those with AD. There was Significant differences, in the sayings 1 (p = 0.033) and 2 (p = 0.001), corresponding to lower sentences, which did not occur with the proverb 3. As for age no verified significant difference among the healthy and only saying 3 in AD patients, however schooling differenced the healthy.ConclusionElderly with Alzheimer's disease at an initial stage have lower performance in the comprehension of ambiguous sentences, interpretation and abstraction of proverbs, corroborating with the data of the literature. The size of these sentences appears to be inversely proportional to the correctness of interpretation in elderly patients with and without AD.

scholarly journals C-15 Serotonergic System Activity and BPSD in Alzheimer’s Disease Pathogenesis: A Systematic Review

2019 ◽  
Vol 34 (6) ◽  
pp. 1044-1044 ◽  
Author(s):  
J Lennon ◽  
B Sytsma ◽  
A Mohit ◽  
S Patel
Keyword(s):  
Systematic Review ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Serotonergic System ◽  
Data Selection ◽  
Pharmacological Intervention ◽  
Ongoing Research ◽  
Recurrent Seizure ◽  
Visual Spatial ◽  
The Impact

Abstract Objective The 5-hydroxytryptamine (5-HT) system is heavily implicated in behavioral and psychological symptoms of dementia (BPSD), with substantial bases for ongoing research in Alzheimer’s disease (AD). This system is directly tied to the hypothalamic-pituitary-adrenal axis. This systematic review aims to accomplish the following objectives: 1) introduce noteworthy BPSD found in AD; 2) synthesize research on 5-HT and BPSD in AD; 3) discuss neuropsychological sequelae of serotonergic dysregulation in AD; and, 4) report future research directions. Data Selection Data Selection: We conducted a literature search of the Medline, PubMed, psychINFO, and Google Scholar databases using the following keywords: Alzheimer’s*, seroton* (serotonin, serotonergic), 5-HT* (5-HTR, 5-HTT*), neuropsychology, behavior*, cogniti*. From the list of studies obtained through this search, we then employed the following inclusion criteria: 1) individuals in study had a formal diagnosis of probable or suspected AD; 2) individuals in study had not previously experienced head trauma, recurrent seizure, or other neurological insult; 3) sample did not include participants with comorbid personality disorders. Data Synthesis Findings suggest that serotonin’s receptors (5-HTRs), transporter (5-HTT), metabolite (5-HTP), and transporter-linked polymorphic region (5-HTTLPR) are linked to depression, anxiety, hyperactivity/impulsivity, aggression, and apathy in AD. Further, 5-HT and resultant BPSD are implicated in numerous cognitive functions including but not limited to decision-making, visual-spatial deficits, attention and vigilance, episodic memory, global cognitive function. Conclusions Substantial evidence exists implicating the serotonergic system in BPSD in AD. By understanding the impact of 5-HT on disease trajectory, neurocognitive functioning, and neuropsychological test performance, clinicians can ensure that appropriate recommendations are made for psychosocial and pharmacological intervention.

scholarly journals P3-618: THE IMPACT OF FOOD PROVISION STUDIES ON ALZHEIMER'S DISEASE: A SYSTEMATIC REVIEW

2019 ◽  
Vol 15 ◽  
pp. P1214-P1214
Author(s):  
Joseph Martinez ◽  
Juanita A. Draime ◽  
Julia C. Gardner ◽  
Sarah E. Berman ◽  
Aleda M.H. Chen
Keyword(s):  
Systematic Review ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Food Provision ◽  
The Impact

scholarly journals THE IMPACT OF DEMENTIA STIGMA IN RECRUITING PARTICIPANTS INTO RESEARCH STUDIES

2019 ◽  
Vol 3 (Supplement_1) ◽  
pp. S592-S593
Author(s):  
Karen Rose ◽  
Ruth Palan Lopez
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Best Practices ◽  
Family Caregivers ◽  
Healthcare Providers ◽  
Prior Work ◽  
Supportive Services ◽  
Related Stigma ◽  
The Impact ◽  
Research Studies

Abstract Despite efforts to increase awareness and education about Alzheimer’s disease and other dementias, persons with dementia and their family caregivers experience stigma. Dementia related stigma is associated with negative repercussions for those with the disease and their family caregivers. In our prior work, we identified shame as a mechanism by which stigma is enacted and results in isolating and delaying access to supportive services for family caregivers. As such, stigma may influence decisions to participate in research studies. Healthcare providers, friends and family, and society, in general, play roles that further perpetuate stigma in dementia. Best practices from the literature, coupled with our experiences and findings in recruiting persons with dementia and their family caregivers in to research studies will be examined.

Sign in / Sign up

Export Citation Format

Share Document